These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 20445343)

  • 21. PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.
    Schilbach K; Schick J; Wehrmann M; Wollny G; Simon P; Schlegel PG; Eyrich M
    Transplantation; 2007 Jul; 84(2):214-22. PubMed ID: 17667813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Restoring function in exhausted CD8 T cells during chronic viral infection.
    Barber DL; Wherry EJ; Masopust D; Zhu B; Allison JP; Sharpe AH; Freeman GJ; Ahmed R
    Nature; 2006 Feb; 439(7077):682-7. PubMed ID: 16382236
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regulatory T cells attenuate experimental periodontitis progression in mice.
    Garlet GP; Cardoso CR; Mariano FS; Claudino M; de Assis GF; Campanelli AP; Avila-Campos MJ; Silva JS
    J Clin Periodontol; 2010 Jul; 37(7):591-600. PubMed ID: 20642629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival.
    Gao W; Demirci G; Strom TB; Li XC
    Transplantation; 2003 Sep; 76(6):994-9. PubMed ID: 14508368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppression of bystander T helper 1 cells by iris pigment epithelium-inducing regulatory T cells via negative costimulatory signals.
    Sugita S; Horie S; Yamada Y; Keino H; Usui Y; Takeuchi M; Mochizuki M
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2529-36. PubMed ID: 19959639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human corneal endothelial cells expressing programmed death-ligand 1 (PD-L1) suppress PD-1+ T helper 1 cells by a contact-dependent mechanism.
    Sugita S; Usui Y; Horie S; Futagami Y; Yamada Y; Ma J; Kezuka T; Hamada H; Usui T; Mochizuki M; Yamagami S
    Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):263-72. PubMed ID: 18775867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.
    Fisicaro P; Valdatta C; Massari M; Loggi E; Biasini E; Sacchelli L; Cavallo MC; Silini EM; Andreone P; Missale G; Ferrari C
    Gastroenterology; 2010 Feb; 138(2):682-93, 693.e1-4. PubMed ID: 19800335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In-vitro generation and characterisation of murine CD4+CD25+ regulatory T cells with indirect allospecificity.
    Tsang J; Jiang S; Tanriver Y; Leung E; Lombardi G; Lechler RI
    Int Immunopharmacol; 2006 Dec; 6(13-14):1883-8. PubMed ID: 17161341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.
    Kitazawa Y; Fujino M; Wang Q; Kimura H; Azuma M; Kubo M; Abe R; Li XK
    Transplantation; 2007 Mar; 83(6):774-82. PubMed ID: 17414712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
    Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
    Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the programmed Death-1 pathway in the suppressive activity of alternatively activated macrophages in experimental cysticercosis.
    Terrazas LI; Montero D; Terrazas CA; Reyes JL; Rodríguez-Sosa M
    Int J Parasitol; 2005 Nov; 35(13):1349-58. PubMed ID: 16126211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.
    Wang L; Han R; Hancock WW
    Eur J Immunol; 2007 Oct; 37(10):2983-90. PubMed ID: 17899549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Deoxyribonucleic acid (DNA) encoding a pan-major histocompatibility complex class II peptide analogue augmented antigen-specific cellular immunity and suppressive effects on tumor growth elicited by DNA vaccine immunotherapy.
    Teramoto K; Kontani K; Ozaki Y; Sawai S; Tezuka N; Nagata T; Fujino S; Itoh Y; Taguchi O; Koide Y; Asai T; Ohkubo I; Ogasawara K
    Cancer Res; 2003 Nov; 63(22):7920-5. PubMed ID: 14633722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
    VanOosten RL; Griffith TS
    Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of interferon-α-transduced tumor cell vaccines and blockade of programmed cell death-1 on the growth of established tumors.
    Omori R; Eguchi J; Hiroishi K; Ishii S; Hiraide A; Sakaki M; Doi H; Kajiwara A; Ito T; Kogo M; Imawari M
    Cancer Gene Ther; 2012 Sep; 19(9):637-43. PubMed ID: 22790963
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma.
    Kawano M; Itonaga I; Iwasaki T; Tsumura H
    Oncol Rep; 2013 Mar; 29(3):1001-6. PubMed ID: 23291864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The adjuvant effect of TLR agonists on CD4(+) effector T cells is under the indirect control of regulatory T cells.
    Olivier A; Sainz-Perez A; Dong H; Sparwasser T; Majlessi L; Leclerc C
    Eur J Immunol; 2011 Aug; 41(8):2303-13. PubMed ID: 21538349
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.